MARTINSRIED / MUNICH, Germany, Feb. 17, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that it has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a Phase 1 clinical trial. The HuCAL-derived, fully human antibody will be developed in the therapeutic area of inflammatory diseases.
Help employers find you! Check out all the jobs and post your resume.
